Drug Safety

RheumNow Podcast – Mistakes with Steroids

Save

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

GLP-1 Therapy in Knee Osteoarthritis

Save

Knee osteoarthritis is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable. The use of anti-diabetic glucagon-like peptide-1 therapies have demonstrated significant weight loss benefits; hence this trial evaluated the potential weight loss and

Implementing Smoking Cessation Programs

Save

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Rheumatology Care Derailed by COVID-19

Save

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.

Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Reactogenicity Following mRNA COVID-19 Vaccines

Save

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Rituximab in Systemic Sclerosis?

Save

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Save

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Save

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.

Janus kinase

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Save

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

Data derived from the retrospective

Serious Infections Still Common in Vasculitis

Save

Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Save

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

1. 
   

   Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

Save

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA. Several noteworthy ones were

Safety of Paternal DMARD or Biologic Use

Save

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

Save

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

Save

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr. Stanley Cohen detailed many issues